Journal of the American College of Cardiology




دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
    http://medilib.ir
  • ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
  • قیمت : 3,800,000 تومان
  • قیمت ویژه : 1,900,000تومان
سفارش

Audio Summary

doi : 10.1016/S0735-1097(21)06119-2

Volume 78, Issue 15, 12 October 2021, Page e105

خرید پکیج و مشاهده آنلاین مقاله


Contents

doi : 10.1016/S0735-1097(21)06121-0

Volume 78, Issue 15, 12 October 2021, Pages e107-e110

خرید پکیج و مشاهده آنلاین مقاله


On-Treatment Blood Pressure and Cardiovascular Outcomes in Adults With Hypertension and Left Ventricular Hypertrophy

Hyeok-HeeLeeMDab?HokyouLeeMDab?So Mi JemmaChoPhDaDong-WookKimPhDcSunghaParkMD, PhDbdHyeon ChangKimMD, PhDab

doi : 10.1016/j.jacc.2021.08.015

Volume 78, Issue 15, 12 October 2021, Pages 1485-1495

Benefits of intensive blood pressure lowering on health outcomes have been demonstrated in high-risk patients. However, little is known about such benefits in patients with left ventricular hypertrophy (LVH).

خرید پکیج و مشاهده آنلاین مقاله


On-Treatment Hypertension Control in a Real-World Cohort: Lower Blood Pressure Remains Better?

S. AndrewMcCulloughMDaDavid C.GoffJr.MD, PhDbPeter M.OkinMDa

doi : 10.1016/j.jacc.2021.08.014

Volume 78, Issue 15, 12 October 2021, Pages 1496-1498

خرید پکیج و مشاهده آنلاین مقاله


Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT

KazumaOyamaMD, PhDabRobert P.GiuglianoMD, SMaMichael A.BlazingMDcJeong-GunParkPhDaAndrew M.TershakovecMD, MPHdMarc S.SabatineMD, MPHaChristopher P.CannonMDaEugeneBraunwaldMDa

doi : 10.1016/j.jacc.2021.08.011

Volume 78, Issue 15, 12 October 2021, Pages 1499-1507

The 2018 U.S. cholesterol management guideline recommends additional lipid-lowering therapy with ezetimibe for secondary prevention in very high-risk patients with low-density lipoprotein cholesterol (LDL-C) ?70 mg/dL despite maximally tolerated statin.

خرید پکیج و مشاهده آنلاین مقاله


Treatment Thresholds and ASCVD Risk?

VeraBittnerMD, MSPH

doi : 10.1016/j.jacc.2021.08.029

Volume 78, Issue 15, 12 October 2021, Pages 1508-1510

خرید پکیج و مشاهده آنلاین مقاله


Biventricular Myocardial Fibrosis and Sudden Death in Patients With Brugada Syndrome

ChrisMilesMBChB, PhDaAngelikiAsimakiPhDaIrina ChisSterMSc, PhDbMichaelPapadakisMDaBelindaGrayMBBS, PhDacdJosephWestabyBMBS, MScaGherardoFinocchiaroMD, PhDaeCarlosBueno-BetiPhDaBodeEnsamMBChBaJoyeeBasuBMBCh, MAaGemmaParry-WilliamsMBChBaHamishMacLachlanMBBSaKhari A.EdwardsMScaDavidJohnsonPhDaMaiteTomeMD, PhDaSanjaySharmaMDaMary N.SheppardMBBCh, MDa?Elijah R.BehrMD, MAa?

doi : 10.1016/j.jacc.2021.08.010

Volume 78, Issue 15, 12 October 2021, Pages 1511-1521

Electrophysiological, imaging, and pathological studies have reported the presence of subtle structural abnormalities in hearts from patients with Brugada syndrome (BrS). However, data concerning disease involvement outside of the right ventricular outflow tract are limited.

خرید پکیج و مشاهده آنلاین مقاله


Myocardial Histopathology Studies in Brugada Syndrome Decedents: Structural Features of a Presumed Electrical Disease?

BabkenAsatryanMD, PhDKatja E.OdeningMDTobiasReichlinMD

doi : 10.1016/j.jacc.2021.08.016

Volume 78, Issue 15, 12 October 2021, Pages 1522-1524

خرید پکیج و مشاهده آنلاین مقاله


Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT

PrakritiGabaMDaDeepak L.BhattMD, MPHaRobert P.GiuglianoMD, SMaPh. GabrielStegMDbMichaelMillerMDcEliot A.BrintonMDdTerry A.JacobsonMDeSteven B.KetchumPhDfRebecca A.JulianoPhDfLixiaJiaoPhDfRalph T.DoyleJr.BAfCraigGranowitzMD, PhDfJean-ClaudeTardifMDgChristie M.BallantyneMDhDuane S.PintoMD, MPHiMatthew J.BudoffMDjC. MichaelGibsonMDi

doi : 10.1016/j.jacc.2021.08.009

Volume 78, Issue 15, 12 October 2021, Pages 1525-1537

REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial) randomized statin-treated patients with elevated triglycerides to icosapent ethyl (IPE) or placebo. There was a significant reduction in adjudicated events, including the primary endpoint (cardiovascular [CV] death, myocardial infarction [MI], stroke, coronary revascularization, unstable angina requiring hospitalization) and key secondary endpoint (CV death, MI, stroke) with IPE.

خرید پکیج و مشاهده آنلاین مقاله


Investigator-Reported Versus Adjudicated Clinical Events: 2 Versions of the Truth??

Stephen J.GreeneMDabJavedButlerMD, MPH, MBAc

doi : 10.1016/j.jacc.2021.08.023

Volume 78, Issue 15, 12 October 2021, Pages 1538-1540

خرید پکیج و مشاهده آنلاین مقاله


Microvascular Resistance Reserve for Assessment of Coronary Microvascular Function: JACC Technology Corner

BernardDe BruyneMD, PhDab?Nico H.J.PijlsMD, PhDc?EmanueleGallinoroMDadAlessandroCandrevaMDaStephaneFournierMDbDanielle C.J.KeulardsMDcJeroenSonckMDaeMarcelvan’t VeerMS, PhDcfEmanueleBarbatoMD, PhDaeJozefBartunekMD, PhDaMarcVanderheydenMDaEricWyffelsMDaAnnemiekDe VosMDcMohamedEl FarissiMDcPim A.L.ToninoMD, PhDcOlivierMullerMD, PhDbCarlosColletMD, PhDaWilliam F.FearonMDg

doi : 10.1016/j.jacc.2021.08.017

Volume 78, Issue 15, 12 October 2021, Pages 1541-1549

The need for a quantitative and operator-independent assessment of coronary microvascular function is increasingly recognized. We propose the theoretical framework of microvascular resistance reserve (MRR) as an index specific for the microvasculature, independent of autoregulation and myocardial mass, and based on operator-independent measurements of absolute values of coronary flow and pressure. In its general form, MRR equals coronary flow reserve (CFR) divided by fractional flow reserve (FFR) corrected for driving pressures. In 30 arteries, pressure, temperature, and flow velocity measurements were obtained simultaneously at baseline (BL), during infusion of saline at 10 mL/min (rest) and 20 mL/min (hyperemia). A strong correlation was found between continuous thermodilution-derived MRR and Doppler MRR (r = 0.88; 95% confidence interval: 0.72-0.93; P < 0.001). MRR was independent from the epicardial resistance, the lower the FFR value, the greater the difference between MRR and CFR. Therefore, MRR is proposed as a specific, quantitative, and operator-independent metric to quantify coronary microvascular dysfunction.

خرید پکیج و مشاهده آنلاین مقاله


Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention: JACC Review Topic of the Week

Alexander E.SullivanMDaMichael G.NannaMD, MHSbTracy Y.WangMD, MHS, MSccDeepak L.BhattMD, MPHdDominick J.AngiolilloMD, PhDeRoxanaMehranMDfSubhashBanerjeeMDgSarahCantrellMLIShW. SchuylerJonesMDcJennifer A.RymerMDcJeffrey B.WashamPharmDiSunil V.RaoMDcE. MagnusOhmanMDc

doi : 10.1016/j.jacc.2021.08.013

Volume 78, Issue 15, 12 October 2021, Pages 1550-1563

Patients undergoing early surgery after coronary stent implantation are at increased risk for mortality from ischemic and hemorrhagic complications. The optimal antiplatelet strategy in patients who cannot discontinue dual antiplatelet therapy (DAPT) before surgery is unclear. Current guidelines, based on surgical and clinical characteristics, provide risk stratification for bridging therapy with intravenous antiplatelet agents, but management is guided primarily by expert opinion. This review summarizes perioperative risk factors to consider before discontinuing DAPT and reviews the data for intravenous bridging therapies. Published reports have included bridging options such as small molecule glycoprotein IIb/IIIa inhibitors (eptifibatide or tirofiban) and cangrelor, an intravenous P2Y12 inhibitor. However, optimal management of these complex patients remains unclear in the absence of randomized controlled data, without which an argument can be made both for and against the use of perioperative intravenous bridging therapy after discontinuing oral P2Y12 inhibitors. Multidisciplinary risk assessment remains a critical component of perioperative care.

خرید پکیج و مشاهده آنلاین مقاله


High-Quality Peer Review of Clinical and Translational Research: A Practical Guide

Fred M.KusumotoMDaJohn A.BittlMDbMark A.CreagerMDcHarold L.DauermanMDdAnuradhaLalaMDeMary M.McDermottMDfJustine VarieurTurcoMAgViviany R.TaquetiMD, MPHhACC’s Scientific Publications Committee’s Peer Review Work Group

doi : 10.1016/j.jacc.2021.06.055

Volume 78, Issue 15, 12 October 2021, Pages 1564-1568

خرید پکیج و مشاهده آنلاین مقاله


Population Health: Intersecting Technology, Data, Health Equity to Achieve Health Care Transformation

DiptiItchhaporiaMD, FACC(President, American College of Cardiology)

doi : 10.1016/j.jacc.2021.09.001

Volume 78, Issue 15, 12 October 2021, Pages 1569-1572

خرید پکیج و مشاهده آنلاین مقاله


Prognostic Role of Pericardial Fat on the Incidence of Heart Failure

StefanoBonapaceMDGiulioMolonMDAlessioMarinelliMDLauraLanzoniMDGiovanniTargherMD

doi : 10.1016/j.jacc.2021.06.053

Volume 78, Issue 15, 12 October 2021, Page e111

خرید پکیج و مشاهده آنلاین مقاله


Reply: Prognostic Role of Pericardial Fat on the Incidence of Heart Failure

SatishKenchaiahMD, MPHMatthew J.BudoffMDJingzhongDingPhDJ. JeffreyCarrMD, MSCEDavid A.BluemkeMD, PhD

doi : 10.1016/j.jacc.2021.08.008

Volume 78, Issue 15, 12 October 2021, Pages e113-e115

خرید پکیج و مشاهده آنلاین مقاله


What Is Behind the HbA1c Value?

AtsushiTanakaMD, PhDKoichiNodeMD, PhD

doi : 10.1016/j.jacc.2021.06.054

Volume 78, Issue 15, 12 October 2021, Page e117

خرید پکیج و مشاهده آنلاین مقاله


Reply: What Is Behind the HbA1c Value?

XavierRosselloPhDBorjaIbanezPhDValentinFusterPhD

doi : 10.1016/j.jacc.2021.08.012

Volume 78, Issue 15, 12 October 2021, Page e119

خرید پکیج و مشاهده آنلاین مقاله


آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟